Head and Neck Cancer Recurrence: What to Ask

"Head and neck cancer" is a group, not one disease. NCI keeps separate clinical summaries for each subsite, including the oropharynx and the larynx. Treatment lists differ between them.

So the first thing to pin down is where the original cancer was, and where it has come back. A recurrence in the same site is handled differently from one in a nearby lymph node, and differently again from spread to the lung. The pages below draw on NCI's oropharyngeal summary, which covers the most common site.

NCI's list of options for recurrent oropharyngeal cancer starts with surgery. The order is not accidental.

Surgical removal is listed first, but the order of a list is not a ranking of what suits you. NCI frames it around a recurrence that is technically operable and did not respond to radiation. A second operation is listed separately, where the tumor was not fully removed the first time. Whether either is right depends on the subsite, HPV status where it applies, how much disease there is, the interval since the last treatment, and whether you are well enough for the operation.

So the opening question is simple. Has a head and neck surgeon looked at the imaging? And has that surgeon said whether this is removable?

Radiation therapy is on the list too. NCI's wording is specific: it applies when surgery did not fully remove the tumor, and when curative doses have not been given to that area before. That is a description of the straightforward case, not a bar. Where curative doses were given, some centres will still consider re-irradiation, weighing the earlier dose and fields against what the surrounding tissue can take.

That makes the old radiation record a live document, not history. Ask what dose that area already got. Then ask whether it leaves room for more.

Where more radiation is possible, NCI names two approaches:

• Conventional or hyperfractionated radiation with chemotherapy given at the same time. Hyperfractionated means smaller doses more than once a day.
• Stereotactic body radiation therapy with cetuximab. This delivers a high dose very precisely, in few sessions.

Sometimes neither surgery nor more radiation is possible. Then treatment becomes systemic, meaning drugs that travel through the body. For squamous cell disease, one lab number comes into the conversation early. It is an input, not the decision: histology, how fast the disease is moving, your symptoms and fitness, and what you have already had all count.

The PD-L1 combined positive score, or CPS, measures PD-L1 staining. It counts staining on tumor cells and immune cells together. It is worth asking for as a number.

KEYNOTE-048 shows how common each level is. It enrolled 882 patients. All had untreated, incurable metastatic or recurrent head and neck squamous cell carcinoma. Of those, 754, or 85%, had a CPS of 1 or higher. And 381, or 43%, had a CPS of 20 or higher. PD-L1 positivity was not required to enter the trial.

The trial ran at 200 sites in 37 countries. It randomized patients three ways. One arm got pembrolizumab alone. One got pembrolizumab plus a platinum drug and fluorouracil. One got cetuximab plus a platinum drug and fluorouracil.

Median overall survival with pembrolizumab alone versus cetuximab with chemotherapy:

• CPS of 20 or higher: 14.9 months versus 10.7 months.
• CPS of 1 or higher: 12.3 months versus 10.3 months.
• All patients: 11.6 months versus 10.7 months, which met the bar for noninferiority.

Median overall survival with pembrolizumab plus chemotherapy versus cetuximab with chemotherapy:

• All patients: 13.0 months versus 10.7 months.
• CPS of 20 or higher: 14.7 months versus 11.0 months.
• CPS of 1 or higher: 13.6 months versus 10.4 months.

Two findings from the same trial deserve equal weight in a decision.

First, side effects differ sharply. Serious events hit 55% of the pembrolizumab-alone group. They hit 85% of the pembrolizumab-plus-chemotherapy group. And 83% of the cetuximab-plus-chemotherapy group. Deaths from side effects ran 8%, 12%, and 10%.

Second, look at what did not improve. At the second interim analysis, neither pembrolizumab arm improved progression-free survival. Overall survival improved while scan-based progression did not. That is worth knowing before the first scan after treatment starts.

Platinum-based chemotherapy is often the first-line choice for metastatic or recurrent head and neck squamous cell carcinoma.

A phase III trial tested adding cetuximab to platinum plus fluorouracil. It enrolled 442 previously untreated patients. Median survival was 10.1 months with cetuximab and 7.4 months without. Quality of life did not get worse with the addition.

One question here is settled. Tumor EGFR gene copy number did not predict who benefits from cetuximab in that setting. So that test result does not decide the drug.

Afatinib was studied against methotrexate in an open-label phase III trial. Median progression-free survival was 2.6 months with afatinib and 1.7 months with methotrexate. The side effects differ in ways worth discussing. Rash or acne hit 10% with afatinib and 0% with methotrexate. Diarrhea hit 9% versus 2%. Low neutrophils hit under 1% versus 7%.

NCI states that managing recurrent and metastatic oropharyngeal carcinoma is complex. It says the best treatment requires input from several specialties.

That is a claim about process, and it is fair to ask about directly. A recurrence decision often needs three specialists at once. A surgeon, a radiation oncologist, and a medical oncologist read the same scans together. Ask whether the case has been through that review.

NCI also lists clinical trials as an option in this setting. Those trials cover added radiation with chemotherapy, targeted therapy, stereotactic body radiation, and immunotherapy. Immunotherapy blocking the PD-L1 pathway can be used after platinum chemotherapy fails, or up front in metastatic or locally recurrent disease.

Three documents carry most of the weight:

• The original pathology report, including any HPV or p16 result.
• The radiation record, with doses and fields.
• The operative note from any prior surgery.

Ask which options above are being ruled out, and on what grounds. Recurrence care narrows fast. Prior radiation or prior surgery can close a door for good. Knowing which doors are shut makes the remaining choice clearer. Our page on head and neck cancer covers the underlying disease.

• Call 911 or go to an emergency department if you are gasping, choking, or not able to get words out. A recurrence near the airway can narrow it quickly. Go in as well, rather than phoning, if your temperature reaches 100.4°F (38°C) or higher while chemotherapy is running. CDC treats that as a medical emergency, because chemotherapy leaves too few white cells to slow an infection down.
• Call your care team the same day if breathing is harder than it usually is for you, food or drink keeps going down the wrong way.
• Call your care team within a day or two if a new lump or swelling appears in your neck, your voice turns hoarse and stays that way, swallowing starts to hurt, or you get earache on one side that does not settle.

• National Cancer Institute, Oropharyngeal Cancer Treatment (Adult) (PDQ) - Health Professional Version, updated May 14, 2025, accessed August 6, 2026
• National Cancer Institute, Laryngeal Cancer Treatment (Adult) (PDQ) - Health Professional Version, accessed August 6, 2026
• NHS, Laryngeal cancer: symptoms, accessed August 11, 2026
• National Cancer Institute, Laryngeal Cancer Treatment (Adult) (PDQ) - Patient Version, accessed August 11, 2026
• National Cancer Institute, Infection and Neutropenia during Cancer Treatment, accessed August 11, 2026
• CDC, Watch out for fever during cancer treatment, accessed August 13, 2026